This marks the first Beacon platform to be used in France, according to the firms. MImAbs provides research institutions, public technology transfer offices, biotech, and biopharma customers with a fully integrated platform for antibody-based therapeutic development. The Beacon system will replace MImAbs' hybridoma system, according to the firms.

The Beacon system provides multiple benefits, including increased capacity to screen 40,000-100,000 B cells compared to only 1,500-3,000 with the hybridoma system, a reduction in timing by nearly 90%, and the ability to establish cell-based assays with adherent cells.

MImAbs was founded in 2011.

Berkeley Lights reports revenue spike in Q2
Berkeley Lights reported an 82% increase in revenue for the second quarter of 2021 compared to the same period a year ago.

Leveraging optofluidics to make therapeutic antibody discovery easier
The need for speed and accuracy in the development of therapeutic antibodies has prompted Berkeley Lights to upgrade its optofluidic tools to help customers...

Abveris expands antibody discovery offerings with second Beacon system
Abveris has starting using a second Berkeley Lights Beacon optofluidic system to enable expansion of its antibody discovery offerings.

Berkeley Lights offers new assays to aid cell line development
Berkeley Lights has launched Opto Assure, a series of assays that provides yield and product quality data during the early stages of cell line development.